Vertex Pharma drops 10% after halting lung disorder drug
The S&P 500 is back in positive territory with a fractional gain. A look inside the S&P 500 shows V.F. Corp (VFC 81.26, +2.71, +3.5%), PVH Corp (PVH 111.79, +3.07, +2.8%), and NVIDIA (NVDA 716.57, +19.56, +2.8%) leading the benchmark index in gains. NVDA agreed to acquire DeepMap, a startup dedicated to building high-definition maps for autonomous vehicles to navigate the world safely.Conversely, Vertex Pharma (VRTX 194.47, -22.30, -10.3%) is the weakest performer with a 10% decline after halting the development of a lung disorder drug and being downgraded to Neutral from Outperform at Daiwa Securities.